We are committed to relieving the disease and suffering of TB patients who account for one-third of the world's total population. We have worked closely with scientists, medical scientists, and doctors to develop and produce Rifampicin, the first-line drug of choice for treating tuberculosis. Treatment practice concludes that Rifampicin is the irreplaceable first-choice drug in anti-tuberculosis in terms of treatment effect and production process maturity. Our Rifampicin production accounts for more than 60% of the global market share, meeting the treatment needs of the United States, Canada, and Mexico in North America, Germany, Russia, and Ukraine in Europe, South Korea, Thailand, India, Pakistan, Vietnam and Indonesia in Asia, Brazil in Latin America and African countries.